Any of these signs mean you should discard the vial: Cloudiness or turbidity
(The FDA has received more than 700 adverse event reports tied to compounded GLP-1s, but its not clear if the events were caused by the drugs.) The companies also see compounders as a threat to their obesity drug sales, which are estimated to balloon to $100 billion a year by 2030
Tertiary expenses like late fees, shipping and handling if getting your medicine by mail, or travel expenses to retrieve your prescription dont count
The available GLP-1 RA injectables are short or long-acting, and include [5,8-14]: Dulaglutide: Long-acting, once weekly Exenatide: Short-acting, twice a day Exenatide extended release: Long-acting, once weekly Liraglutide: Long-acting, once a day Lixisenatide: Short-acting, once a day Semaglutide: Long-acting, once weekly Combination of GLP-1 medications and exercise Non-medication management strategies for type 2 diabetes involve lifestyle modifications like diet and exercise
GLP-1 drugs are at the center of this transition, acting as a bridge between traditional metabolic care and newer, more patient-driven models
